Oncology Data Advisor i3 Health

In honor of Acute Myeloid Leukemia (AML) Awareness Day, Oncology Data Advisor Editorial Board and Fellows Forum members Tristan Knight, MD, FRCPC, Richa Thakur, MD, and Joseph Kalis, PharmD, BCOP, hosted a live panel discussion covering the evolving treatment landscape for AML, including:
• Novel therapies and combinations such as chimeric antigen receptor (CAR) T-cell therapy and isocitrate dehydrogenase (IDH) inhibitors
• The role of measurable residual disease (MRD) testing
• Considerations for pediatric transplant and cellular therapy
• Words of hope for patients undergoing treatment for AML

Additionally, they answered live questions from the audience, including:
• Do you have any first-line treatment recommendations for patients with a KMT2A mutation?
• When do recommend that patients participate in a clinical trial?

Take a listen to hear the panelists’ answers to these questions and their perspectives on the ever-changing therapeutic landscape for AML!

In honor of Testicular Cancer Awareness Month, Oncology Data Advisor Fellows Forum members Samuel Kareff, MD, MPH, Waqas Haque, MD, MPH, and Matthew Hadfield, DO, sat down to discuss improving early detection, minimizing toxicities of treatment, and optimizing long-term survivorship, particularly for adolescent and young adult (AYA) survivors of testicular cancer.

In celebration of Head and Neck Cancer Awareness Month this April, Oncology Data Advisor Fellows Forum and Editorial Board Members Samuel Kareff, MD, MPH; Matthew Hadfield, DO; and Nagashree Seetharamu, MD, sat down to discuss the epidemiology of head and neck squamous cell carcinomas (HNSCC), the diagnostic and treatment process of HNSCC, including:
–Epidemiologic trends
–Geographic distribution
–Approved screening methods
–Novel treatment combinations
–Side effects and adverse events
–Survivorship
–And more!

This April, Oncology Data Advisor is raising awareness for Esophageal Cancer Awareness Month. In this interview, Oncology Data Advisor Editorial Board and Fellows Forum members Dr. Joseph Kalis, Dr. Matthew Hadfield, and Dr. Samuel Kareff discuss rising trends, treatment advances, and emerging management strategies for esophageal cancer, including the following:
• The rising rate of adenocarcinoma in the context of pre-existing esophageal dysplasia and Barrett esophagus
• Risk factors such as tobacco and alcohol
• The roles of healthy eating and smoking cessation in esophageal cancer prevention
• How the rise of immunotherapies such as pembrolizumab, nivolumab, and trastuzumab have changed practice
• This month’s approval of fam-trastuzumab deruxtecan-nxki for human epidermal growth factor receptor 2 (HER2)–positive solid tumors
• Lifestyle interventions such as following the Mediterranean diet and United States Preventive Services Task Force (USPSTF) exercise guidelines that can make maximize tolerability of therapy

In this interview from the American Association for Cancer Research (AACR) 2024 Annual Meeting, Dr. Alankrita Taneja, third-year Hematology/Oncology Fellow at Roswell Park Cancer Institute and Oncology Data Fellows Forum Member, speaks with Dr. Sundar Jagannath, Professor of Medicine (Hematology and Medical Oncology) and Director of the Center of Excellence for Multiple Myeloma at the Mount Sinai Icahn School of Medicine and Tisch Cancer Institute.

At the meeting, Dr. Jagannath presented results of the phase 1/2 LINKER-MM1 trial of linvoseltamab, a CD3-directed B-cell maturation antigen (BCMA) antibody under investigation for relapsed/refractory multiple myeloma. In this follow-up conversation, Dr. Jagannath shares further insights into the trial, including:
• The study design, which includes triple-class–refractory patients
• The unique dosing schedule of linvoseltamab, which reduces the frequency of administration to improve patient convenience
• The response, survival, and measurable residual disease (MRD) negativity outcomes demonstrated in the trial, including among high-risk patients
• Management of side effects, including cytokine release syndrome (CRS), neutropenia, anemia, and infections
• The future role of linvoseltamab in the treatment landscape for relapsed/refractory multiple myeloma as it advances through investigation
• And more!

In this interview, Jason Mouabbi, MD, an Oncology Data Advisor Editorial Board Member and Assistant Professor in the Department of Breast Oncology at the University of Texas MD Anderson Cancer Center, sat down with Valerie Brutus, MD, FACS, a Breast Surgical Oncologist at St. Vincent's Medical Center of Hartford HealthCare, and Elizabeth Stirling Craig, MD, Director of Microvascular Breast Reconstruction at St. Vincent's Medical Center of Hartford HealthCare, to discuss improving breast cancer surgical outcomes with lymphovenous bypass surgery.

Dr. Mouabbi engages Dr. Brutus and Dr. Craig in a thought-provoking discussion about lymphovenous bypass surgery: what it is, who qualifies for this procedure, its viability, what to expect from this procedure and its treatment process, and more about breast cancer surgical outcomes.